You are here: Industry Insights > AbbVie

News List

CHMP Recommends Approvals of RINVOQ for the Active Psoriatic Arthritis, Ankylosing Spondylitis americanpharmaceuticalreview
December 31, 2020
AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ™ (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded ...
Upadacitinib Meets Primary, All Ranked Secondary Endpoints in Ulcerative Colitis Study americanpharmaceuticalreview
December 10, 2020
AbbVie announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8, as well as all ranked secondary endpoints ...
Two medicines accepted for use by NHS Scotland pharmatimes
December 09, 2020
The Scottish Medicines Consortium has approved NHS funding for treatments for blood cancer and a rare muscle disorder.
AbbVie partners with Frontier Medicines on protein degrader development pharmatimes
December 04, 2020
AbbVie has announced a new partnership with precision medicine company Frontier Medicines to discover and develop small molecules therapeutics for difficult-to-treat protein targets.
AbbVie’s Venclyxto gets NICE blood cancer backing pharmatimes
November 12, 2020
AbbVie’s Venclyxto (venetoclax) has been recommended for use by the National Institute of Health and Care Excellence (NICE) as a routine treatment for chronic lymphocytic leukaemia (CLL).
NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis pharmatimes
November 09, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Rinvoq (upadacitinib) for people with previously treated severe active rheumatoid arthritis (RA).
Allergan Announces Positive Phase 3 Topline Results for Presbyopia Trial americanpharmaceuticalreview
November 05, 2020
Allergan, an AbbVie company, announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with ...
Financial Report; Abbvie contractpharma
November 02, 2020
Revenue up 52% in the quarter to $12.9 billion.
VENCLEXTA Receives FDA Approval for AML americanpharmaceuticalreview
October 22, 2020
AbbVie announced the U.S. Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia ..
AbbVie’s Venclexta granted full US approval in AML pharmatimes
October 22, 2020
The US Food and Drug Administration (FDA) has fully approved AbbVie’s Venclexta in acute myeloid leukaemia (AML).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page